Key result
Targeting the CD146-HIF-1α axis with anti-CD146 antibodies or genetic ablation mitigated pulmonary vascular remodeling and alleviated established pulmonary hypertension in rodent models.
Why the study?
No cure is currently available for pulmonary arterial hypertension due to an incomplete understanding of vascular remodeling.
Population
Chronic hypoxic mice and two rodent models of pulmonary hypertension
Comparison
Genetic ablation of Cd146 in SMCs or anti-CD146 antibodies vs controls
Design
Preclinical animal and cellular study
Authors
Loading...
Hypothesis-generating for CD146-targeted therapy in pulmonary hypertension; human trials needed before clinical consideration.
Targeting the CD146-HIF-1α cross-regulation axis mitigates pulmonary vascular remodeling and alleviates pulmonary hypertension in rodent models, offering a potential therapeutic strategy for PAH.
Luo et al. (2019) studied Pulmonary arterial hypertension. Anti-CD146 antibodies or genetic ablation of Cd146 vs. Control antibody or Wild-type was evaluated on Pulmonary vascular remodeling and right ventricular systolic pressure (RVSP). Targeting the CD146-HIF-1α axis with anti-CD146 antibodies or genetic ablation mitigated pulmonary vascular remodeling and alleviated established pulmonary hypertension in rodent models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: